PEPCLUB.me

Neurological & Nerve HealthInflammation SupportRegeneration & RecoveryArticlePremium

ARA-290 / Cibinetide

10mg Vial

2 September 2026Updated 2 September 2026

Overview Research15 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for ARA-290 / Cibinetide.

Create free account Member login

Full range of benefits for ARA-290 / Cibinetide

Activates the innate repair receptor (IRR) to mediate cytoprotection

Non-erythropoietic—does not increase red blood cell mass or hematocrit

Modulates inflammation and can reduce pro-inflammatory cytokine release

May reduce neuropathic pain symptoms observed in clinical studies

Promotes small-fiber nerve repair and regeneration in preclinical and clinical work

Improves corneal nerve fiber density on clinical imaging assessments

Protects tissues from ischemia-reperfusion injury in animal models

May improve sensory function and nerve conduction measures in neuropathy

Can produce relatively rapid symptomatic effects in short-term studies

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 16 known interactions

Synergistic(4)Compatible(4)Monitor(4)Avoid(4)

Generally well-tolerated alongside this peptide

Statins

No known pharmacokinetic or pharmacodynamic interaction with ARA‑290 and commonly administered safely in the same patient population.

Metformin

Widely used in diabetic patients with no reported interactions or need for routine adjustment when coadministered with ARA‑290.

Beta‑blockers

No documented interactions or additive adverse effects with ARA‑290, making them generally compatible for concomitant use.

Antibiotics (e.g., doxycycline)

No direct interactions expected between standard antimicrobial agents and ARA‑290, allowing concomitant treatment of infections as clinically indicated.

All interaction categories

Synergistic (4)

Gabapentinoids (gabapentin, pregabalin): Complementary mechanisms for neuropathic pain control — ARA‑290 reduces neuroinflammation and promotes repair while gabapentinoids reduce neuronal hyperexcitability, often improving analgesic efficacy when combined.
SNRIs (duloxetine, venlafaxine): Central pain modulation provided by SNRIs can be additive to ARA‑290's peripheral anti‑inflammatory and neuroprotective effects, enhancing overall neuropathic pain and functional outcomes.
ACE inhibitors / ARBs: Both classes provide renoprotective and anti‑inflammatory effects that may be complementary to ARA‑290 in patients with diabetic or inflammatory kidney disease, potentially improving renal outcomes.
Physical rehabilitation / neuromodulation (TENS): Rehabilitation and neuromodulation therapies can be synergistic with ARA‑290 by combining functional rehabilitation with the peptide's tissue‑repair and anti‑inflammatory actions to enhance recovery.

Compatible (4)

Statins: No known pharmacokinetic or pharmacodynamic interaction with ARA‑290 and commonly administered safely in the same patient population.
Metformin: Widely used in diabetic patients with no reported interactions or need for routine adjustment when coadministered with ARA‑290.
Beta‑blockers: No documented interactions or additive adverse effects with ARA‑290, making them generally compatible for concomitant use.
Antibiotics (e.g., doxycycline): No direct interactions expected between standard antimicrobial agents and ARA‑290, allowing concomitant treatment of infections as clinically indicated.

Monitor (4)

Erythropoiesis‑stimulating agents (epoetin alfa): Although ARA‑290 is non‑erythropoietic, concomitant use with ESAs warrants monitoring of hemoglobin/hematocrit to detect unexpected hematologic effects or excessive erythropoiesis.
Immunosuppressants / biologic DMARDs (methotrexate, TNF inhibitors): Combined immunomodulatory therapy may increase infection risk or alter immune markers, so monitor clinical signs of infection and relevant laboratory parameters.
Anticoagulants (warfarin, DOACs): Systemic inflammation changes can affect coagulation; monitor INR or other relevant coagulation tests if clinical status changes when starting or stopping ARA‑290.
Nephrotoxic or renally‑eliminated drugs (NSAIDs, aminoglycosides): Patients receiving ARA‑290 for renal indications or with compromised renal function should have renal function monitored when coadministered potentially nephrotoxic or renally‑cleared agents.

Avoid (4)

Pregnancy and breastfeeding: Insufficient human safety data exist for ARA‑290 in pregnancy or lactation, so use only if potential benefits justify potential risks and after specialist review.
Live vaccines: Because ARA‑290 has immunomodulatory effects and may be used with other immunosuppressants, live vaccines should be used with caution and timing reviewed by a clinician.
High‑dose systemic corticosteroids: Concomitant high‑dose corticosteroids may produce overlapping immunosuppression and increase infection risk, requiring reassessment of risk–benefit before combination therapy.
Erythropoiesis‑stimulating therapies or uncontrolled thrombotic disorders: Although ARA‑290 is designed to be non‑erythropoietic, patients with active thrombotic disease or on therapies that alter erythropoiesis should be evaluated carefully due to theoretical vascular risk.